Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)
Shots:
- The US FDA has approved Darzalex Faspro (daratumumab & hyaluronidase-fihj) + bortezomib, lenalidomide & dexamethasone (D-VRd) as induction & consolidation therapy for newly diagnosed MM patients who can undergo ASCT
- Approval was supported by the P-III (PERSEUS) trial, carried out with the European Myeloma Network, which assessed D-VRd vs VRd during induction & consolidation among NDMM patients who can go for ASCT
- Trial met its 1EP, showing improved PFS of 60% & MRD negativity rate of 57.5% vs 32.5% and 76.6% vs 58.5% among patients who achieved CR or better
Ref: Johnson & Johnson | Image: Johnson & Johnson
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
